 |
MabThera works in leukaemia says RocheSwiss drugmaker Roche said a study showed its top-selling cancer drug MabThera delayed disease progression in patients with relapsed or refractory Chronic Lymphocytic Leukaemia, or CLL. MabThera is known as Rituxan in the United States, wh More… |
Friday 3 May 2024
